{"log_id": 8969741457849241399, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.008034, "average": 0.96725, "min": 0.550651}, "location": {"width": 743, "top": 198, "height": 29, "left": 292}, "words": "1.严禁本品与单胺氧化酶抑制剂(包括抗生素类药物利奈唑胺,一种可逆,非选择性"}, {"probability": {"variance": 0, "average": 0.999996, "min": 0.999996}, "location": {"width": 35, "top": 208, "height": 32, "left": 1161}, "words": "药"}, {"probability": {"variance": 0.000131, "average": 0.995413, "min": 0.944113}, "location": {"width": 472, "top": 240, "height": 24, "left": 254}, "words": "的单胺氧化酶抑制剂)合用(见【禁忌】和【警告】)"}, {"probability": {"variance": 0.090483, "average": 0.692324, "min": 0.39152}, "location": {"width": 41, "top": 251, "height": 27, "left": 1161}, "words": "准"}, {"probability": {"variance": 0.008072, "average": 0.96785, "min": 0.568636}, "location": {"width": 743, "top": 279, "height": 29, "left": 293}, "words": "与大多数抗抑郁药一样,本品不能与单胺氧化酶抑制剂合,服用本品前后两周内不能"}, {"probability": {"variance": 0.001353, "average": 0.991094, "min": 0.770941}, "location": {"width": 780, "top": 317, "height": 29, "left": 255}, "words": "使用单胺氧化酶抑制剂。在停用单胺氧化酶抑制剂两周后开始服用本品时应慎重量应逐"}, {"probability": {"variance": 0, "average": 0.999476, "min": 0.998813}, "location": {"width": 62, "top": 360, "height": 24, "left": 253}, "words": "渐增加"}, {"probability": {"variance": 0.00042, "average": 0.993285, "min": 0.880979}, "location": {"width": 742, "top": 398, "height": 27, "left": 293}, "words": "2.由于严重室性心律失常和猝死的风险都可能与甲硫嗪血药浓度升高有关,故禁忌"}, {"probability": {"variance": 7.5e-05, "average": 0.99316, "min": 0.977004}, "location": {"width": 221, "top": 438, "height": 24, "left": 254}, "words": "帕罗西汀和甲硫哒嗪合用"}, {"probability": {"variance": 0.00478, "average": 0.97237, "min": 0.644567}, "location": {"width": 739, "top": 478, "height": 25, "left": 292}, "words": "3.哌迷清( (Pimozide):一项单次低剂量(2毫克)哌迷清与帕罗西汀联合给药的试验"}, {"probability": {"variance": 0.002091, "average": 0.988036, "min": 0.700717}, "location": {"width": 780, "top": 515, "height": 28, "left": 254}, "words": "显示,哌迷清水平升高。这是由于帕罗西汀具有CYP2D6抑制的特性。并且由于哌迷清治疗"}, {"probability": {"variance": 0.000278, "average": 0.992276, "min": 0.904186}, "location": {"width": 715, "top": 556, "height": 24, "left": 252}, "words": "指征狭窄和已知它能延长QT间期,因此严禁哌迷清与本品合并使用(见【禁忌】)"}, {"probability": {"variance": 0.006595, "average": 0.971069, "min": 0.606953}, "location": {"width": 741, "top": 594, "height": 25, "left": 293}, "words": "4.血清素能药物:和其它选择性5-HT再摄取抑制剂( SSRIS)药物一样,和血清素能药"}, {"probability": {"variance": 0.011485, "average": 0.964936, "min": 0.477129}, "location": {"width": 448, "top": 632, "height": 25, "left": 253}, "words": "物合用可能导致5-HT相关效应(见【警告】)的发生"}, {"probability": {"variance": 0.006801, "average": 0.976168, "min": 0.502306}, "location": {"width": 743, "top": 671, "height": 25, "left": 292}, "words": "当血清素能药物(如色胺酸,曲坦类药物,曲马多,5H再摄取抑制剂 SSRIS,锂、芬"}, {"probability": {"variance": 0.015959, "average": 0.949843, "min": 0.472224}, "location": {"width": 760, "top": 711, "height": 25, "left": 254}, "words": "太尼、和St.John'sort贯叶连翘一制剂)与本品合用的时候需谨慎并密切监测临床病情"}, {"probability": {"variance": 0.008139, "average": 0.970438, "min": 0.524859}, "location": {"width": 743, "top": 750, "height": 25, "left": 292}, "words": "阿米替林(5羟色胺受体激动剂):罕见有使用SSRT和阿米替林发生5-羟色胺综合征"}, {"probability": {"variance": 0.000342, "average": 0.993975, "min": 0.892233}, "location": {"width": 781, "top": 789, "height": 25, "left": 253}, "words": "的上市后报告,如果临床确实需要合用本品和阿米替林,应密切观察患者病情,尤其是在治"}, {"probability": {"variance": 2e-06, "average": 0.998552, "min": 0.995354}, "location": {"width": 261, "top": 829, "height": 24, "left": 250}, "words": "疗的起始阶段以及增加剂量时"}, {"probability": {"variance": 0.006222, "average": 0.980326, "min": 0.55351}, "location": {"width": 727, "top": 866, "height": 25, "left": 293}, "words": "华法林:初步资料显示,帕罗西汀和华法林之间有药效学相互作用(在凝血酶原时"}, {"probability": {"variance": 0.000805, "average": 0.987742, "min": 0.871145}, "location": {"width": 623, "top": 906, "height": 24, "left": 253}, "words": "间不变的情况下出血增加)。由于临床经验少,本品与华法林合用应谨慎"}, {"probability": {"variance": 0.00424, "average": 0.976943, "min": 0.721678}, "location": {"width": 424, "top": 944, "height": 26, "left": 302}, "words": "推荐本品与5羟色胺前体物质(如色氨酸)合用"}, {"probability": {"variance": 0.005929, "average": 0.982899, "min": 0.511693}, "location": {"width": 744, "top": 984, "height": 26, "left": 290}, "words": "5.药物代谢酶;药物代谢酶的诱导剂或抑制剂可影响本品的代谢和药代动力学,当本品"}, {"probability": {"variance": 0.000523, "average": 0.992326, "min": 0.861082}, "location": {"width": 779, "top": 1023, "height": 25, "left": 255}, "words": "与已知的药物代谢酶抑制剂合用时,应考虑使用剂量范围的低限。而当本品与已知的药物代"}, {"probability": {"variance": 0.009567, "average": 0.97846, "min": 0.371397}, "location": {"width": 784, "top": 1060, "height": 25, "left": 252}, "words": "谢酶诱导剂(如:马西平、利福平、苯巴比妥、苯妥英)合用时,则无须考虑调整初始剂"}, {"probability": {"variance": 0.009258, "average": 0.97429, "min": 0.510766}, "location": {"width": 479, "top": 1099, "height": 25, "left": 253}, "words": "量。随后剂量的调整应视临床反应(疗效及耐受性)而定"}, {"probability": {"variance": 0.01072, "average": 0.959264, "min": 0.666547}, "location": {"width": 183, "top": 1138, "height": 23, "left": 434}, "words": "利托那韦:本品与F"}, {"probability": {"variance": 5.8e-05, "average": 0.993781, "min": 0.977059}, "location": {"width": 295, "top": 1138, "height": 24, "left": 740}, "words": "利托那韦合用时会显著降低帕罗西"}, {"probability": {"variance": 2.9e-05, "average": 0.997103, "min": 0.976926}, "location": {"width": 635, "top": 1176, "height": 26, "left": 252}, "words": "汀的血浆浓度,应根据临床效果(耐受性和有效性)进行任何的剂量调整"}, {"probability": {"variance": 0.007824, "average": 0.974497, "min": 0.610418}, "location": {"width": 299, "top": 1215, "height": 25, "left": 293}, "words": "1)帕罗西汀对CYP2D6的抑制效能"}, {"probability": {"variance": 0.01433, "average": 0.957984, "min": 0.487713}, "location": {"width": 738, "top": 1253, "height": 26, "left": 295}, "words": "和其他抗抑郁药物(包括其他 SSRIS)一样,帕罗西汀会抑制肝脏细胞色素P450酶CYP2DE"}, {"probability": {"variance": 0.000263, "average": 0.993229, "min": 0.906385}, "location": {"width": 778, "top": 1294, "height": 25, "left": 255}, "words": "抑制CYP2D6可能导致合用的经该酶代谢的药物血浆浓度升高。这些药物包括某些三环类抗"}, {"probability": {"variance": 0.000128, "average": 0.994214, "min": 0.933368}, "location": {"width": 782, "top": 1333, "height": 24, "left": 253}, "words": "抑郁药(如,阿米替林,去甲替林,丙咪嗪和地昔帕明)、吩噻嗪类精神安定药物(如,奋乃"}, {"probability": {"variance": 0.004984, "average": 0.976778, "min": 0.589995}, "location": {"width": 780, "top": 1370, "height": 26, "left": 254}, "words": "静和甲硫哒嗪,见【禁忌)、利培酮、阿托西汀、某些1e类的抗心律失常药(如,普罗帕"}, {"probability": {"variance": 0.003023, "average": 0.981682, "min": 0.807884}, "location": {"width": 214, "top": 1411, "height": 25, "left": 253}, "words": "酮和氟卡尼)和美托洛尔"}, {"probability": {"variance": 0.000336, "average": 0.991702, "min": 0.882611}, "location": {"width": 741, "top": 1449, "height": 27, "left": 294}, "words": "他莫西芬是需CYP2D6代谢激活的前体药物,帕罗西汀对CYP2D6的抑制可能导致一种活"}, {"probability": {"variance": 3.2e-05, "average": 0.997749, "min": 0.978614}, "location": {"width": 478, "top": 1488, "height": 24, "left": 254}, "words": "性代谢物的血浆浓度降低,因而降低了他莫西芬的疗效"}], "language": 3}